Evaluating the oncogenic risk of residual DNA in vaccines: the potential role of transgenic mice.
There is a general consensus that residual DNA from immortalised cells is very unlikely to pose a safety risk for biotechnology products but there is little experimental data to support this contention. Transgenic mice primed with one or more oncogenes or tumour suppressor deletions offer a potentially sensitive and quantitative method for determining the presence of oncogenic DNA. Separate lines of mice transgenic for myc and Cbfa1 may provide a means of detecting oncogenic DNA containing genes belonging to different complementation groups.
Onions
D
D
Department of Veterinary Pathology, The University of Glasgow, and Q-One Biotech Ltd, Scotland, UK.
D000818:Animals; D002461:Cell Line, Transformed; D050659:Core Binding Factor Alpha 1 Subunit; D004247:DNA / Q000502:physiology*; D016147:Genes, Tumor Suppressor; D016259:Genes, myc; D005816:Genetic Complementation Test; D051379:Mice; D008822:Mice, Transgenic; D009363:Neoplasm Proteins; D009374:Neoplasms, Experimental / Q000235:genetics* / Q000473:pathology; D014157:Transcription Factors / Q000235:genetics
D050659:Core Binding Factor Alpha 1 Subunit; D009363:Neoplasm Proteins; D014157:Transcription Factors; D004247:DNA